Acurx Pharmaceuticals announces 1-for-20 reverse stock split effective August 4, 2025 to regain Nasdaq compliance

Acurx Pharmaceuticals, Inc.

Reverse split ratio 1-for-20; effective 4:01 p.m. ET on August 4, 2025.
Post-split trading begins August 5, 2025 under ticker ACXP; new CUSIP 00510M 203.
Outstanding shares reduced from ~30.8M to ~1.5M; authorized shares unchanged.
Fractional shares paid in cash based on August 1, 2025 closing price.
Split approved by stockholders at July 17, 2025 annual meeting; intended to regain Nasdaq minimum bid price compliance.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Acurx Pharmaceuticals, Inc.: Filing of certificate of amendment to effect a 1-for-20 reverse stock split of common stock, effective August 4, 2025 at 4:01 p.m. Eastern Time (effective 2025-08-04).

Change: charter amendment
Effective: 2025-08-04

Exact text from the filing

On July 31, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its certificate of incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-20 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-072529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.